

Anti-TROP2 (Sacituzumab), Humanized Antibody

rev 10/20

CATALOG NO.: A2175-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a recombinant antibody to Sacituzumab without the drug conjugation. The original antibody-drug conjugate (Sacituzumab Govitecan) consists of an anti-TROP2 humanized monoclonal antibody (RS7-3G11) that is chemically linked to a cytotoxic drug SN-38 via a hydrolyzable CL2A linker. Upon internalization in the cell, the SN-38 is released from the antibody via the hydrolysis of the CL2A linker. SN-38 inhibits DNA topoisomerase I and induces DNA-damage mediated cell death. The original antibody-drug conjugate received approval from the FDA in 2020 to treat patients with metastatic triple-negative breast cancer who have received at least two prior treatment regimens.

ALTERNATE NAMES: IMMU-132, hRS7-SN-38, hRS7-SN-38-ADC, hRS7-[CL-SN-38], hRS 7SN38, hRS7-SN38, IMMU 132, EGP1, GP50, M1S1, EGP-1, TACSTD2, GA7331, GA733-1

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Human TROP2

CAS NUMBER: 1491917-83-9

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C. Avoid freeze/thaw cycles

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)

Anti-VEGF (Bevacizumab), Humanized Antibody (A1045)

Anti-HER2 (Pertuzumab), Humanized Antibody (A2111)

Anti-HER2 Humanized Antibody (A1046)

Anti-PD-L1 Humanized Antibody (A1305)

FOR RESEARCH USE ONLY! Not to be used on humans.